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ABSTRACT
Infective endocarditis is a microbial infection of the endocardial surface and, despite improvements in
diagnostic accuracy, medical therapy and surgical techniques, mortality remains high. This review
focuses on changes in epidemiology, microbiology and diagnosis, as well as changes in medical and
surgical management of infective endocarditis affecting native and prosthetic valves in adults, that have
evolved during the past two decades. Signiﬁcant changes have included an increasing involvement of
prosthetic valves and nosocomially-acquired disease, an increased involvement of staphylococci as the
causative agents, and a recognition that elderly individuals with degenerative valvular disease are the
most vulnerable population. Topics still requiring study include whether and when valve replacement
should be performed, and how to predict perivalvular complications or embolisation based on
echocardiography ﬁndings. Optimisation of antimicrobial treatment schemes (choice of the antibiotic,
dose and duration) also requires further investigation.
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INTRODUCTION
Excellent reviews of infective endocarditis (IE)
were published in the 1970s and 1980s [1–4].
However, this disease has undergone consider-
able changes during more recent years [5,6]. This
review describes new trends in clinical presenta-
tion, patient population, underlying heart disease,
microbiology and management of IE.
Deﬁnition and classiﬁcation
IE is deﬁned as a microbial infection of the
endocardial surface. Previously, IE was classiﬁed,
according to its presentation, as acute, sub-acute
or chronic [7]. The present classiﬁcation refers to
the activity of the disease and its recurrence
rate, the diagnostic status (deﬁnite ⁄possible), the
anatomical site (left ⁄ right side), whether it is
native valve IE (NVE) or prosthetic valve
IE (PVE), and the microbiology of the disease
(i.e., microorganism implicated and culture ⁄ ser-
ology ⁄PCR ⁄histology results). The characterisa-
tion of the patient population has also become an
important topic (i.e., whether elderly, or charac-
terised by nosocomial IE, congenital heart disease,
intravenous drug abuse, etc.) [8].
PVE is classiﬁed as early or late, depending on
when infection occurs: early PVE occurs within
2 months of surgery; late PVE occurs at least
12 months after surgery; and intermediate PVE
occurs between 2–12 months after surgery [6,9].
Although some studies classify late PVE as IE
occurring >2 months after surgery, most authors
agree that the ‘late’ cut-off should be after 1 year
[5,10].
Nosocomial IE is deﬁned as IE that occurs
>72 h after admission to a hospital, or within
4–8 weeks of a hospital-based invasive procedure
[9,11,12], although it has been proposed that this
deﬁnition should be extended to include episodes
occurring within 6 months of discharge [11,13].
Epidemiology
The epidemiological features of NVE are chang-
ing as a result of increased longevity, which has
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given rise to more degenerative valvular disease,
increased placement of prosthetic valves, and
increased exposure to the possibility of nosoco-
mial bacteraemia and long-term haemodialysis
[9,10,14–17]. The mean age in IE series varies
between 36 and 69 years, and the incidence
increases with age. The male:female ratio is 2:1,
with a median incidence of IE in the population of
3.6 ⁄ 100 000 ⁄ year [9,10]. The incidence of PVE is
increasing and reaches 20–30% of all IE cases in
large series. The risk of PVE is 1% at 12 months,
and 2–3% at 60 months [9,10,13,15]. Mechanical
valves are probably at higher risk for infection
than bioprostheses during the ﬁrst 3 months after
surgery, but the rates of infection later converge
for the two valve types, and are similar after
5 years [5,6]. The incidence of nosocomial IE is
7–29%, but is increasing because more patients
are hospitalised in intensive care units or undergo
invasive procedures [7,10–12,17].
There is a decreasing proportion of NVE,
probably because of a lower incidence of rheu-
matic valvular disease. Nowadays, NVE occurs
mainly in patients with no previously known
heart disease. Degenerative changes are thought
to be the predisposing condition [7,9,10,16]. The
valve affected most frequently is the mitral valve
(45 ) 50% of cases), followed by the aortic valve
(35 ) 39%) and the tricuspid valve (19%). Rarely,
IE is found on the pulmonic valve (1.5–2%), or
on extravalvular localisations such as a pace-
maker lead, the atrial septum, ventricular
wall, chordae tendineae or mural endocardium
[10,17–19].
In cases of PVE, the aortic valve is involved
more frequently [15,20]. Both the aortic and mitral
valve are affected in 15% of cases, and at least
21% of cases have two sites infected simulta-
neously [10,18].
Microbiology
The microbiology of IE depends on whether IE
occurs on an NV or PV, and whether the disease
is hospital- or community-acquired [9,15,16].
Staphylococcus aureus, Streptococcus spp. and
Enterococcus spp. are responsible for >80% of all
cases of IE.
An important evolving trend is that Staph.
aureus has emerged as the most common cause
of IE, while rates of infection caused by viridans
group streptococci are decreasing [10,14–17,20–
23]. These ﬁndings correlate with recent observa-
tions in which the portal of entry is more often
cutaneous than dental [9,10,16]. The prevalence of
IE among patients with Staph. aureus bacteraemia
varies between 13 and 25%. The frequency of
enterococcal IE is <10% among patients with
enterococcal bacteraemia [10,12].
An important subgroup of Gram-negative
bacteria associated with IE is the HACEK group
(1–4%; i.e., Haemophilus spp., Actinobacillus actin-
omycetemcomitans, Cardiobacterium hominis, Eikenel-
la corrodens and Kingella kingae). It is estimated
that Bartonella spp. cause 3% of all cases of IE [24].
Non-bacterial or atypical agents, such as Chlamy-
dia, fungi and viruses, have also been implicated
in IE. Fungi cause <10% of cases of IE overall, but
among these, Candida spp. are the most common
pathogens [12].
Early cases of PVE (within 2 months of sur-
gery) are usually hospital-acquired and result
from inoculation during surgery, or follow a
central venous catheter infection.
Late PVE cases (>12 months after surgery) are
largely community-acquired, while cases of PVE
occurring 2–12 months after surgery are a mixture
of hospital-acquired episodes caused by less
virulent organisms and community-acquired epi-
sodes [5,6,10]. Coagulase-negative staphylococci
(CNS) are the most frequent cause of early PVE,
followed by Staph. aureus and Enterococcus spp.
The microbiological aetiology of late PVE does
not differ signiﬁcantly from that of NVE, regard-
less of whether the cut-off is placed at 2 months
or 1 year.
Nosocomial IE is caused more often by staphy-
lococci than is community-acquired IE; staphylo-
cocci are responsible for >75% of cases of
nosocomial IE, with a Staph. aureus:CNS ratio of
c. 3:1 [11,12,16]. Following haemodialysis, Staph.
aureus is the causative organism in >50% of cases
[5,14]. The pathogens isolated most commonly
among cases of procedure-related IE are Entero-
coccus spp. in association with urogenital and
gastrointestinal procedures, and Staph. aureus in
association with skin incision or soft-tissue mani-
pulation [11,12].
Some studies with patients aged >60 years
have found that Strep. bovis is the causative
organism in 10% of cases, and have noted that
Strep. bovis is accompanied in c. 45% of cases by
abnormalities of the digestive tract, particularly
colon carcinoma and villous adenoma [6,25].
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There is also an association between Strep. gallo-
lyticus and pre-cancerous intestinal polyps [26].
In cases of intravenous drug abuse, the most
frequent pathogens are Staph. aureus, Pseudomonas
aeruginosa and fungi [7,17]. Polymicrobial IE is
generally uncommon and occurs mostly in associ-
ation with intravenous drug abuse [6,7]. In intra-
venous drug users infected with human
immunodeﬁciency virus (HIV), the risk and mor-
tality from IE rise inversely with the CD4 count (if
<500 cells ⁄lL) and the responsible pathogens are
sometimes unusual, e.g., Bartonella, Salmonella or
Listeria [5].
Course and complications
Fever is an important criterion when following
the evolution of IE. IE caused by Strep. viridans
responds more quickly to antibiotics than does IE
caused by Staph. aureus or Enterococcus spp.
Fever often resolves within 2–5 days following
the start of appropriate antibiotics for patients
with less virulent pathogens, and defervescence
occurs in 90% of patients by the end of the
second week of treatment. Persistent fever
beyond the ﬁrst week often indicates the devel-
opment of complications [10,13,16,17]. Recurrent
fever, mostly observed in the third or fourth
week of treatment, is often caused by drug
hypersensitivity (often to b-lactam antibiotics),
although reactive arthritis and emboli may still
occur at this later stage and cause fever [6]. Half
of all cases of IE have at least one complication,
amongst which cardiac and neurological events
predominate [10,13,16,17].
Peri-annular extension and abscess formation
are frequent in NVE (10–40%), affecting especi-
ally the aortic valve, and are very common in PVE
(56–100%). Extension beyond the valve annulus is
predictive of higher mortality, more frequent
development of congestive heart failure, and the
need for cardiac surgery.
Congestive heart failure is the most common
life-threatening complication and the principal
cause of death in IE patients. In cases of conges-
tive heart failure, the usual cause is infection-
induced valvular damage; aortic valve infection is
associated more frequently with heart failure than
is mitral valve infection [6,7]. Other cardiac
complications are cardiac rupture and tampon-
ade, tunnels and ﬁstulas, pseudo-aneurysms, ring
abscesses, sinus of Valsalva aneurysms, peri-
carditis and myocarditis. Involvement of the
conduction system, resulting in dysrhythmia,
atrioventricular, fascicular or bundle-branch
block, is more frequent in PVE and native aortic
valve IE than in native mitral valve IE [6,7].
The predominant complications of PVE are
peri-prosthetic leaks and dehiscence.
Embolism or fragments of vegetations may
cause an acute myocardial infarction (coronary
emboli) [17,27]. Neurological complications
develop in 20–40% of cases, most of which are
stroke or transient ischaemic attacks. Other neu-
rological manifestations include brain abscess,
brain haemorrhage caused by aneurysm rupture
or bleeding in ischaemic stroke, aseptic menin-
gitis, toxic encephalopathy and seizures [7,10,13,
16,17].
The possibility of embolic events is at a maxi-
mum during the ﬁrst 2 weeks of IE, and becomes
less frequent with longer durations of therapy
[21,27]. Left-sided IE may be complicated by
systemic embolism, and the central nervous sys-
tem is involved most frequently. Other sites
include spleen, kidney, liver, skin, iliac and
mesenteric arteries. Mycotic aneurysms may
involve any artery, i.e., the aorta, cerebral arteries,
visceral arteries and arteries of the extremities
[7,10,13,16,17].
The role of echocardiography and the mor-
phological features of the vegetation in predict-
ing embolisation remain controversial, but most
studies conclude that vegetation size is correla-
ted with the risk of embolisation and, in
particular, large vegetations on the mitral valve,
especially the anterior leaﬂet, are associated
with a higher risk of embolisation than are
vegetations of similar size elsewhere [5,6,10,17,
21,23,27–30].
Acute renal failure is a complication of IE, and
is indicative of a poor prognosis. Glomerulone-
phritis is the most frequent type of renal involve-
ment, followed by ischaemic infarction.
Right-sided IE may be complicated by pul-
monary manifestations, such as pulmonary
artery embolism and infarction, pneumonia,
lung abscess and right heart failure. There are
usually no peripheral stigmata. Cough and
pleuritic chest pain occur in 40–60% of cases,
while haemophtysis and dyspnoea occur occa-
sionally. Chest X-ray reveals nodular inﬁltrates,
multifocal pneumonia, effusions or pyopneumo-
thorax.
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Diagnosis
The diagnosis of IE involves an integration of
clinical, laboratory and echocardiographic data.
The Duke criteria (Table 1) have replaced the
Beth Israel or Von Reyn criteria because of a
substantially higher sensitivity and negative
predictive value, which is mainly attributed to
the use of echocardiographic ﬁndings [31–36].
The Duke criteria have been shown to be highly
speciﬁc for ruling out IE in patients with acute
fever or fever of unknown origin [33]. Modiﬁca-
tions of the Duke criteria have been proposed.
Thus, the minor criterion ‘echocardiogram con-
sistent with IE, but not meeting a major criter-
ion’ should be eliminated, given the use
of transoesophageal echocardiography (TEE).
Recent guidelines suggest that TEE is the
preferred initial diagnostic test for patients in
whom IE is suspected on the basis of clinical
criteria, for patients with suspected complicated
IE, and for patients with suspected PVE [8,37]. In
addition, bacteraemia caused by Staph. aureus,
and positive Q-fever serology, are now consid-
ered to be major criteria [5,37]. Other suggested
modiﬁcations to increase the sensitivity of the
Duke criteria include the use of TEE and
serological ⁄molecular biological ﬁndings in cul-
ture-negative cases, and the inclusion of further
minor criteria, such as newly developed club-
bing, splenomegaly and a C-reactive protein
(CRP) level of >100 mg ⁄L [8].
Blood cultures are the most important labor-
atory diagnostic test, and also provide suscep-
tibility test results for bacteria [9,25]. The
current recommendation calls for at least three
blood culture sets to be drawn from different
peripheral venipuncture sites, irrespective of
body temperature, within the ﬁrst 24 h of
admission, spaced at least 1 h apart, in order
to differentiate IE from contamination. This
procedure can be repeated on the second day
[9,13,38]. Blood cultures remain sterile in only
5–7% of cases [12,24]. Negative blood cultures
are caused most frequently by antibiotic con-
sumption within the previous 2 weeks [7,31].
Other reasons for culture-negative endocarditis
are fastidious and difﬁcult-to-cultivate micro-
organisms, such as the HACEK group, Bartonella
spp., Coxiella burnetti, Brucella spp., Legionella
spp., Mycoplasma spp. or intracellular pathogens
[7,26,38–40]. Serum should always be analysed
for antibodies to organisms that cannot be
cultured by routine methods, such as C. burnetti
and Bartonella. Cross-reactions of Bartonella anti-
bodies with Chlamydia antibodies have been
described [24,37,38].
PCR can be used to identify unculturable
organisms in excised vegetations or systemic
emboli, and is of particular value when no
serological test is available, e.g., in the case of
Tropheryma whipplei [26,31,38,40]. Positive PCR
results must always be interpreted within the
clinical context because they can remain positive
for several months after long-term treatment with
antibiotics.
Excised valves, vegetations or other material
should undergo microscopy and histopathology
with the necessary staining to detect T. whipplei,
Bartonella and C. burnetti; fungal IE can also be
diagnosed by histopathology [24,31]. The pres-
ence of organisms following Gram’s stain of
ground valve material or by histopathological




Positive blood cultures (= 2 ⁄ 2) with typical IE micro-organisms:
viridans group streptococci, Streptococcus bovis, HACEK group,
Staphylococcus aureus, or community-acquired enterococci in the
absence of primary focus
Persistently positive blood cultures (two culture sets drawn >12 h apart,
or three of four culture sets with the ﬁrst and last separated by ‡ 1 h)
Single positive culture for Coxiella burnetti or antibody titre against
phase I of >1:800
Endocardial involvement
Positive echocardiogram for IE
(i) oscillating intracardiac mass on valve or supporting structure, or in the
path of regurgitant jets, or on implanted material, in the absence of an
alternative explanation, or
(ii) abscess, or
(iii) new partial dehiscence of prosthetic valve
New valvular regurgitation (worsening of changing or pre-existing
murmur not sufﬁcient)
Minor criteria
Predisposing cardiac condition or intravenous drug use
Fever (‡ 38 C)
Vascular factors: major arterial emboli, septic pulmonary infarct,
mycotic aneurysms, intracranial haemorrhage, conjunctival haemorrhage,
Janeway’s lesions
Immunological factors: glomerulonephritis, Osler nodes, Roth spots,
rheumatoid factor
Microbiological factors: positive blood cultures, but not meeting major criteria,
serological evidence of active infection with plausible micro-organisms
Echocardiogram consistent with disease but not meeting major criteria
Diagnosis
Deﬁnite
Pathology or bacteriology of vegetations, major emboli,
or intracardiac abscess specimen, or
Two major criteria, or
One major and three minor criteria, or
Five minor criteria
Possible
One major and one minor criteria, or Three minor criteria
Rejected
Firm alternative diagnosis, or
Resolution of syndrome after £4 days of antibiotherapy, or
No pathological evidence at surgery or autopsy after £4 days of antibiotic therapy
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examination does not mean, however, that viable
organisms are present [20].
TREATMENT
Medical treatment
No comparative studies exist to determine the
most effective antimicrobial treatment for IE [41].
Based upon insight into the pathogenesis of the
disease, experimental animal data and clinical
experience, long-term parenteral bactericidal anti-
biotics in high concentrations are considered to be
the cornerstone of treatment, with the choice of
regimen determined by antibiotic susceptibility
testing. Treatment guidelines have been devel-
oped by working parties of major scientiﬁc
societies, of which the most renowned are the
recommendations of the American Heart Associ-
ation and, more recently, of the European Society
of Cardiology [8,42,43]. These guidelines offer
a solid framework for adequate antimicrobial
therapy for a devastating disease.
In the case of severe sepsis, severe valvular
dysfunction, conduction disturbances or embolic
events, immediate empirical therapy is indicated
after taking three blood cultures; this empirical
therapy should later be adjusted according to the
microbiological test results [44]. Linezolid is a new
treatment option for methicillin-resistant Staph.
aureus (MRSA), glycopeptide-intermediate Staph.
aureus (GISA) and vancomycin-resistant Entero-
coccus (VRE). Both success and failure have been
reported for IE cases treated with linezolid
[45–49]. For Q fever IE, optimal treatment adds
hydroxychloroquine to doxycycline. Prescription
of this combination for at least 18 months allows
the duration of therapy to be decreased and results
in a reduction in the number of relapses [50].
Anticoagulant therapy
Anticoagulation and aspirin have not been shown
to prevent embolisation in IE, and may increase
the risk of intracerebral haemorrhage. Anticoagu-
lant therapy for NVE is restricted to patients with
a clear indication separate from IE. In the pres-
ence of intracranial haemorrhage or mycotic
aneurysm, anticoagulant therapy should be with-
drawn until the complications have resolved.
For PVE which requires maintenance anti-
coagulation, anticoagulant therapy should be
prescribed cautiously in the presence of central
nervous system emboli with haemorrhage, and
temporary discontinuation seems appropriate [6].
Patients with Staph. aureus PVE who are receiving
anticoagulant therapy are particularly susceptible
to central nervous system haemorrhage, and it
has therefore been suggested that anticoagulant
therapy should be suspended during the acute
phase of the illness [6].
Outpatient treatment
Some IE patients may eventually become candi-
dates for outpatient treatment, but all patients
should be treated in hospital for at least 2 weeks
and observed for complications, especially
embolic events [8]. Outpatient treatment can be
considered for patients who are medically stable
(i.e., no complications of IE, no fever, negative
blood cultures, stable electrocardiogram). Inpa-
tient treatment should be continued for patients
with complications such as congestive heart
failure, conduction abnormalities, mental status
change or evidence of perivalvular abscess on
TEE, and for patients of a high-risk subgroup (i.e.,
acute IE, aortic valve disease, PVE, IE caused by
Staph. aureus or other virulent organisms) [9].
Surgical treatment
The indications for and the timing of surgery are
still a matter of debate. The principal dilemma is
whether to operate early to limit the risk of emboli
and to avoid severe cardiac insufﬁciency, or to
delay surgical intervention until resolution of the
infection in order to reduce the risks of surgery
and secondary PVE.
Valve surgery is performed for at least 25–30%
of patients with active IE, and for 20–40% of
patients in the later phases, even after successful
medical treatment during the active phase [51].
Surgery clearly improves the outcome when
infection causes severe valve dysfunction, is
uncontrolled by antibiotics, or when recurrent
embolisation occurs, and delays in surgery are
associated with increased morbidity and mortal-
ity [20,52].
The impact of early surgical intervention is
signiﬁcant in patients with a pacemaker, congen-
ital or prosthetic heart disease, and in patients
with Staph. aureus IE [53,54].
Hill et al. Trends in infective endocarditis 9
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12, 5–12
The mean surgical mortality rate is 12%, with
survival of 75% at 5 years, and of 61% at
10 years. Improvements in outcome may result
from improved medical and surgical manage-
ment, resulting in a decreased surgical mortality
rate. The latter is associated mainly with better
timing of surgery in cases of IE complicated by
congestive heart failure [16,52].
The optimal time to perform surgery is before
severe haemodynamic disability or spread of the
infection to perivalvular tissue has occurred.
Serial echocardiograms may be helpful to monitor
the need for valve surgery [6]. Signiﬁcant post-
operative paravalvular leakage occurs in <5% of
patients [10,29]. The rate of recurrent PVE after
surgery for IE has been reported to be up to 7%
during a 6-year follow-up period [6].
Because the frequency at which emboli occur
decreases rapidly with effective antibiotics, the
beneﬁt of surgery in preventing further emboli is
greatest if performed early in the course of IE.
However, in cases of ischaemic cerebrovascular
accidents, surgery could carry a risk of haemor-
rhage because of the anticoagulation measures
needed for extracorporal circulation [27]. The
risks for post-operative neurological deterioration
or death mean that a recent neurological compli-
cation of IE has been considered to be a relative
contraindication for valve-replacement surgery
[6]. However, other studies have found that
cardiac surgery after a cerebral embolism in order
to prevent a recurrent episode is not contraindi-
cated if performed within 72 h. If not performed
early, it is preferable to postpone surgery for
3–4 weeks [8].
Widely accepted indications for surgery are
summarised in Tables 2 and 3 [9,18,52–56]. A
prosthetic valve is a common indication for
possible surgery, but there is no clear evidence
that all patients with PVE should receive surgery.
Patients with PVE who can be treated with
antibiotics alone are usually characterised by
clinical stability, good evolution with antibiotic
treatment, early diagnosis, late onset of infection,
infection by Strep. viridans or HACEK organisms,
and no evidence of perivalvular extension [57].
Current recommendations for the management
of Staph. aureus IE favour a combination of
medical therapy and early surgery [6,21,53,54].
The approach should be conservative for right-
sided IE, and surgery is indicated only if fever
persists for >3 weeks of adequate antibiotic treat-
ment. Recurrent pulmonary inﬁltrates are not an
indication for surgery.
Post-surgical treatment
The aim of post-surgical treatment should be to
eradicate cardiac infection and potentialmetastatic
infectious foci [8]. The duration of antibiotic treat-
ment after valve replacement surgery for active IE
has not been assessed in carefully controlled
studies, but it is accepted that it should take into
consideration the length of pre-operative therapy,
the presence of perivalvular extension, and the
microbiological and pathological ﬁndings at sur-
gery [6,20]. In all cases, the normal full treatment
course must be completed, and treatment should
be continued for at least 7–15 days post-surgery.
Another full course of antibiotic therapy should be
completed after surgery for NVE or PVE if a
positive valve culture is found, regardless of the
duration of treatment before surgery [8].
Outcome
Lower mortality rates have been observed during
the last three decades, but the overall mortality
for NVE and PVE remains at 20–25% after 1 year,
and at 50% after 10 years [10,39,51]. The
in-hospital mortality rate of hospital-acquired IE
Table 2. Indications for surgery with native valve endo-
carditis (NVE)
Heart failure caused by acute mitral ⁄ aortic regurgitation
Persistent fever and bacteraemia for >7–10 days despite adequate antibiotic
therapy
Perivalvular extension: abscess, pseudo-aneurysms, ﬁstulas, rupture of
valve, conduction disturbances, myocarditis
Difﬁcult-to-treat microorganisms (e.g., fungi, Brucella, Coxiella burnetti,
Staphylococcus lugdunensis, Legionella spp., Chlamydia spp., Mycoplasma spp.,
Mycobacterium spp., Bartonella spp., Tropheryma whipplei, Pseudomonas aeruginosa
and multiresistant microorganisms)
Severe native valve obstruction
Vegetations that are mobile and larger than 10 mm on the mitral valve,
or increasing vegetation size despite antibiotic therapy, mitral kissing
vegetations, and recurrent emboli despite adequate antibiotic therapy
Table 3. Indications for surgery with prosthetic valve
endocarditis (PVE)
Early PVE
Late PVE complicated by prosthesis dysfunction (perivalvular leak, obstruction),
persistent positive blood cultures, abscess formation, conduction abnormalities,
large vegetations, particularly if left-sided valves are involved and
if staphylococci are the infecting agents
Mechanical obstruction ⁄ obstructive vegetations
Haemodynamically signiﬁcant prosthetic valve malfunction
Perivalvular extension
Persistent fever and bacteraemia for >7–10 days despite adequate
antibiotic therapy
Recurrent emboli despite adequate antibiotic therapy
Infections caused by microorganisms with a poor response to antibiotic therapy
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is 24–50%, which is signiﬁcantly higher than for
community-acquired IE (16–20%) [11,12,16,21].
There is no difference in long-term survival
between mitral and aortic valve disease. IE caused
by Staph. aureus and fungi has a worse prognosis
than streptococcal IE. Relapse of IE occurs usually
within 2 months of discontinuation of antimicro-
bial therapy. The relapse rate for Strep. viridans
NVE is <2%, while that for enterococcal NVE is
8–20%. A relapse rate of 11% has been reported
for Staph. aureus IE [6,58].
Epilogue
Recent changes in IE have included an increasing
involvement of PV and nosocomially-acquired
disease, the emergence of staphylococci as import-
ant causative agents, and the recognition that
elderly patientswith degenerative valvular disease
are the most vulnerable population. Many topics
require further study, includingwhether andwhen
valve replacement should be performed, and how
to predict perivalvular complications or embolisa-
tion based on the results of echocardiography
ﬁndings. Optimisation of antimicrobial treatment
regimens (choice of the antibiotic, dose and dur-
ation) also requires further investigation.
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